(Source: Shionogi & Co Ltd) SHIONOGI INC. ANNOUNCES CO-PROMOTION AGREEMENT WITH NOVEN PHARMACEUTICALS FOR BRISDELLE™ (PAROXETINE) CAPSULES FLORHAM PARK, NJ (January 13, 2014) - Shionogi Inc. today announced that it has entered into an exclusive, multi-year agreement with Noven Pharmaceuticals to co-promote Brisdelle™ (paroxetine) capsules, 7.5 mg, the first and only non-hormonal prescription drug approved for the treatment of moderate to severe hot flashes associated with menopause. Under the terms of the agreement, Shionogi will promote Brisdelle, along with Osphena™ (ospemifene), its non- estrogen oral treatment for moderate to severe painful intercourse due to menopause. The co- promote...
↧